The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Can Lupus Be Prevented? Research Reveals Clues to Who’s Most Likely to Transition to Classified Disease

Can Lupus Be Prevented? Research Reveals Clues to Who’s Most Likely to Transition to Classified Disease

February 25, 2020 • By Susan Bernstein

  • Tweet
  • Email
Print-Friendly Version / Save PDF

They compared the immune system profiles of 31 European American, ANA-positive, healthy individuals with those of 31 patients with active SLE not on immunosuppressive therapy and 31 ANA-negative controls matched for age, sex, race and body mass index. They found the ANA-positive, healthy individuals had a unique serum cytokine profile: inflammatory cytokines similar to the lupus patients and levels of suppressive cytokines even lower than in ANA-negative individuals. BLyS levels were elevated in the lupus patients and lower in the healthy controls, but BLyS levels were even lower in the ANA-positive, healthy individuals.

You Might Also Like
  • Biomarkers, Genetic Clues to Higher Cardiovascular Disease Risk in Patients with Lupus
  • 2013 ACR/ARHP Annual Meeting: Clues to Predictors of Autoimmune Disease Revealed
  • New Study Reveals Limitations in ANA Test Kits for Lupus
Explore This Issue
March 2020
Also By This Author
  • Original Sin—Researchers Look for Infectious Triggers of Rheumatic Disease & the Best Options to Block the Process

“When we compared IL-1 receptor antagonist panels, one of our most striking findings was that ANA-negative, healthy individuals tended to have lower levels of IL-1RA, and lupus patients had levels in the middle, but ANA-positive, healthy individuals have really elevated levels,” she said. “This makes for an interesting pathway to consider and one that ANA-positive, healthy individuals may use to suppress the transition to full-blown disease.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Could any autoantibodies protect ANA-positive individuals from transition to lupus? Recent research suggests anti-DFS70 antibodies, or dense-fine speckled autoantibodies that bind to the lens-epithelium-derived growth factor, a stress survival protein, protects the immune system from environmental stressors.16 In a 2018 study of sera from 1,758 individuals, researchers found anti-DFS70 autoantibodies were highly enriched in healthy people and are typically negatively associated with systemic autoimmune disease development, said Dr. James. 17

Is Hydroxychloroquine Protective?
Lupus researchers want to identify any potential early interventions that may prevent disease onset in at-risk individuals. When Dr. James’ team first analyzed the military repository cohort, they documented which individuals had ever received hydroxychloroquine or chloroquine before meeting ACR SLE classification criteria compared with those who had not received these anti-malarial drugs.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“If we looked at time to diagnosis, there was actually a time delay to developing lupus in the group who were treated with hydroxychloroquine compared with those who were not. At the time, I was a little concerned people were being put on hydroxychloroquine because they had lupus symptoms, but some were put on chloroquine because of where they were deployed. We went back and looked at accrual of autoantibodies between those two groups,” said Dr. James.

Accrual of autoantibodies was lower, and then plateaued, in individuals who had received hydroxychloroquine compared with those who did not take the drug. Hydroxychloroquine treatment prior to SLE diagnosis was also associated with a longer mean time between first clinical symptom onset and diagnosis.18

Pages: 1 2 3 4 5 6 7 | Single Page

Filed Under: Conditions, SLE (Lupus) Tagged With: 2019 ACR/ARP Annual Meeting, environmental factor, genetic, SLE, systemic lupus erythematosus (SLE)Issue: March 2020

You Might Also Like:
  • Biomarkers, Genetic Clues to Higher Cardiovascular Disease Risk in Patients with Lupus
  • 2013 ACR/ARHP Annual Meeting: Clues to Predictors of Autoimmune Disease Revealed
  • New Study Reveals Limitations in ANA Test Kits for Lupus
  • Study Reveals Role of IL-17–Secreting CD4+ T Cells in Lupus

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)